Abstracts tagged "Osteoarthritis"

Abstract Number: 1119 • ACR Convergence 2020
Association of Primary Insurance Status on Bilateral Knee Arthroplasty Utilization and Complications: A United States Nationwide Analysis
Bella Mehta¹, Kaylee Ho², Jennifer Bido³, Stavros Memtsoudis³, Michael Parks⁴, Linda Russell⁵, Susan Goodman¹ and Said Ibrahim⁶, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Weill Cornell Medicine, New York, ³Hospital for Special Surgery, New York, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, ⁵Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁶Weill Cornell Medicine, Cleveland, OH
Background/Purpose: In patients with end-stage bilateral knee osteoarthritis, treatment options include either a staged total knee arthroplasty (TKA) procedure, often with a few months in…
Abstract Number: 1485 • ACR Convergence 2020
LNA043, a Novel Cartilage Regenerative Treatment for Osteoarthritis: Results from a First-In-Human Trial in Patients with Knee Osteoarthritis
Celeste Scotti¹, Joseph Gimbel², Didier Laurent¹, Aviv Madar³, Thomas Peters¹, Yunyu Zhang³, Florine Polus¹, Michael Beste³, Igor Vostiar¹, Subhajit Choudhury⁴, Nicole Gerwin¹, Jörg Goldhahn⁵, Matthias Schieker¹ and Ronenn Roubenoff¹, ¹Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Arizona Research Center, Phoenix, ³Novartis Institutes for BioMedical Research, Cambridge, ⁴Biostatistics & Pharmacometrics, Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁵Department of Health Sciences and Technology, ETH Zürich, Zurich, Switzerland
Background/Purpose:LNA043 is a modified human angiopoietin-like 3 (ANGPTL3) protein identified in a phenotypic screen for inducers of chondrogenesis and cartilage repair. The primary objective of…
Abstract Number: 1645 • ACR Convergence 2020
Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program
Luana Colloca¹, Robert Dworkin², John Farrar³, Leslie Tive⁴, Ed Whalen⁵, Jerry Yang⁴, Lars Viktrup⁶, Mark Brown⁷, Christine West⁷ and Kenneth Verburg⁸, ¹University of Maryland, Baltimore, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, New York, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Groton
Background/Purpose: The level of placebo group response in clinical trials for chronic pain conditions is a concern for the development of novel analgesics1. Here, we…
Abstract Number: 1661 • ACR Convergence 2020
Systematic Review and Meta-Analysis of the Prevalence of Neuropathic-Like Pain and Pain Sensitisation in People with Knee and Hip Osteoarthritis
Luigi Zolio¹, Kai Ying Lim², Mabel Yan¹, Mahnuma Estee³, Sultana Monira Hussain⁴, Flavia Cicuttini⁴ and Anita Wluka⁵, ¹Alfred Health, Melbourne, Australia, ²Monash University, Kuala Lumpur, Malaysia, ³Monash University, Melbourne, Australia, ⁴Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, ⁵Monash University, Melbourne, Victoria, Australia
Background/Purpose: Pain in osteoarthritis (OA) may be nociceptive or neuropathic-like in nature. In knee OA, pain severity is known to be poorly correlated with joint…
Abstract Number: 0539 • ACR Convergence 2020
Sports with a Bat or Racket Are Not Associated with Thumb-base Osteoarthritis: Data from the Osteoarthritis Initiative
Jeffrey Driban¹, Grace Lo², Mary Roberts³, Matthew Harkey⁴, Lena Schaefer⁵, Ida Kristin Haugen⁶, Stacy Smith⁷, Jeffrey Duryea⁷, Bing Lu⁸, Charles Eaton⁹, Marc Hochberg¹⁰, Rebecca Jackson¹¹, C. Kent Kwoh¹², Michael Nevitt¹³ and Timothy McAlindon¹, ¹Tufts Medical Center, Boston, MA, ²Michael E. Debakey VA Medical Center, Baylor College of Medicine, Houston, TX, ³Center for Primary Care & Prevention, Alpert Medical School of Brown University, Pawtucket, RI, ⁴University of Massachusetts, Worcester, MA, ⁵Radiology Department, Klinikum Nürnberg Süd, Nürnberg, Germany, ⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁹Brown University, Pawtucket, RI, ¹⁰University of Maryland School of Medicine, Baltimore, MD, ¹¹Ohio State University, Columbus, OH, ¹²University of Arizona of Arizona Arthritis Center and Division of Rheumatology, College of Medicine, University of Arizona, Tucson, AZ, ¹³Department of Epidemiology and Biostatistics, University of California San Francisco, Orinda, CA
Background/Purpose: Sports that require the use of a racket or bat to propel a ball (e.g., baseball, softball, tennis) expose the thumb-base to repetitive high-velocity…
Abstract Number: 0704 • ACR Convergence 2020
The Murine Ear Wound Cartilage Superhealer Trait, Mediated by the Gut Microbiome, Is Transgenerationally Heritable Following Cecal Transplantation
Christopher Dunn¹, Cassandra Garman², Cassandra Velasco², Vladislav Izda², Jake Martin² and Matlock Jeffries², ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: MRL/MpJ mice are substantially protected from developing post-traumatic osteoarthritis (OA), a trait with strong correlation to the ability to heal ear wounds. We have…
Abstract Number: 1104 • ACR Convergence 2020
The Disability Associated with Hand Osteoarthritis Is Substantial in a Cohort of Post-menopausal Women : The QUALYOR Study
Maxime Auroux¹, Blandine Merle², Eric Lespessailles³ and Roland Chapurlat¹, ¹Hospices Civils de Lyon, Lyon Cedex 03, Rhone-Alpes, France, ²INSERM UMR 1033, Université de Lyon, Lyon Cedex 03, Rhone-Alpes, France, ³Regional Hospital and University of Orleans, Orléans, France
Background/Purpose: Osteoarthritis (OA) is a highly prevalent disease, affecting more than 400 millions individuals around the world. Hand osteoarthritis (HOA) is the most frequent form…
Abstract Number: 1120 • ACR Convergence 2020
A Comparison of Opioid-Related Outcomes Among Commercially-Insured Osteoarthritis Patients Treated with Tramadol vs. Non-Tramadol Opioids
Stuart Silverman¹, James Rice², Alan White², Catherine Fernan², Michael Somma², Craig Beck³, Rebecca Robinson⁴ and Patricia Schepman⁵, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Analysis Group, Boston, MA, ³Pfizer, London, ⁴Eli Lilly and Company, Indanapolis, IN, ⁵Pfizer, New York City, NY
Background/Purpose: In 2019, the American College of Rheumatology conditionally recommended tramadol for patients with hip and knee osteoarthritis (OA). While tramadol is known to be…
Abstract Number: 1486 • ACR Convergence 2020
Long-term Efficacy and Safety of Intra-articular Sprifermin in Patients with Knee Osteoarthritis: Results from the 5-Year Forward Study
Felix Eckstein¹, Marc Hochberg², Hans Guehring³, Flavie Moreau⁴, Victor Ona⁴, Asger Bihlet⁵, Inger Byrjalsen⁵, Jeppe Andersen⁵, Benjamin Daelken³, Oliver Guenther³, Christoph Ladel³, Martin Michaelis³ and Philip G Conaghan⁶, ¹Paracelsus Medical University, Salzburg, Austria, ²University of Maryland School of Medicine, Baltimore, MD, ³Merck KGaA, Darmstadt, Germany, ⁴EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁵Nordic Bioscience, Herlev, Denmark, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: The 5-year Phase II FORWARD study assessed the efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin (recombinant human fibroblast growth factor…
Abstract Number: 1646 • ACR Convergence 2020
Use of Prescription Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in Adults with Hip/Knee Osteoarthritis (OA) at Increased Risk for NSAID-related Adverse Events
Jayeshkumar Patel¹, Wenhui Wei², Raveendhara Bannuru³, Ravi Iyer⁴, Nazneen Fatima Shaikh¹, Traci LeMasters¹, Chibuzo Iloabuchi¹, Degang Wang² and Usha Sambamoorthi¹, ¹West Virginia University School of Pharmacy, Morgantown, WV, ²Regeneron Pharmaceuticals, Tarrytown, NY, ³Tufts Medical Center, Boston, MA, ⁴Teva Pharmaceutical Industries, West Chester, PA
Background/Purpose: NSAIDs are commonly used for OA pain, but the benefits of pain relief must be carefully weighed against the potential risk for gastrointestinal (GI),…
Abstract Number: 1662 • ACR Convergence 2020
Do Weight-bearing versus Non-weight-bearing Pain Reflect Different Pain Mechanisms in Knee Osteoarthritis?: The Multicenter Osteoarthritis Study
Jean Liew¹, John Farrar², Na Wang³, Lisa Carlesso⁴, Kosaku Aoyagi³, Laura Frey Law⁵, Cora Lewis⁶, Michael Nevitt⁷ and Tuhina Neogi³, ¹University of Washington, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³Boston University School of Medicine, Boston, MA, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Iowa, Iowa City, IA, ⁶University of Alabama Birmingham, Birmingham, AL, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Pain with weightbearing in knee OA is thought to be related to the activation of nociceptors; however, this is not considered the sole mechanism…
Abstract Number: 0543 • ACR Convergence 2020
Exercise Among Older Adults Living with Rheumatic Disease: Physical Activity Habits and Patient Reported Outcomes
Alexis Ogdie¹, Sofia Pedro², Joshua Baker³, Kaleb Michaud⁴ and Patricia Katz⁵, ¹University of Pennsylvania, Philadelphia, PA, ²FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita, ⁵University of California, San Francisco, Novato, CA
Background/Purpose: Among patients with rheumatic disease, physical activity is important for maintaining health and improving outcomes. EULAR recommendations suggest at least 30 min of vigorous…
Abstract Number: 0705 • ACR Convergence 2020
lncRNA H19 and Micro RNA 675-3p Are Altered by Visfatin During Osteogenesis
Dennis Küppers¹, Lali Tsiklauri², Marie-Lisa Hülser¹, Klaus Frommer², Stefan Rehart³, Caroline Ospelt⁴, Ulf Müller-Ladner⁵ and Elena Neumann⁶, ¹Justus-Liebig-University Giessen, Campus Kerckhoff, Dept. of Rheumatology and Clinical Immunology, Giessen, Germany, ²Justus-Liebig-University Giessen, Campus Kerckhoff, Dept. of Rheumatology and Clinical Immunology, Bad Nauheim, Germany, ³Department of Orthopaedics and Trauma Surgery, Agaplesion Markus Hospital, Frankfurt, Frankfurt, Germany, ⁴University Hospital Zürich; University Hospital of Zurich; Center of Experimental Rheumatology, Department of Rheumatology, Zurich, Switzerland, ⁵Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ⁶Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany
Background/Purpose: Long non-coding (lnc-)RNAs are transcribed from DNA similar to mRNA. lncRNA are able to interact directly with DNA, RNA and proteins. Some lncRNAs contain…
Abstract Number: 1105 • ACR Convergence 2020
RANK-L Activity: Understanding the Pathogenesis of Erosive Osteoarthritis
Kalyna Jakibchuk¹, Javier Rangel-Moreno¹, Bethany Marston², Jennifer Anolik¹ and Allen Anandarajah¹, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Rochester
Background/Purpose: Erosive osteoarthritis (EOA) is characterized by osteoarthritic findings with central erosions and collapse of the interphalangeal joint subchondral bone plate. A number of studies…
Abstract Number: 1121 • ACR Convergence 2020
Osteoarthritis in the Million Veterans Program: Integrating the Electronic Medical Record with Precision Medicine
Merry-Lynn McDonald¹, Preeti Lakshman Kumar¹, Vinod Srinivasasainagendra¹, Joshua Richman¹, Sarah Pinson¹, Alison Rocco¹, Dennis Richard², Vivek Jagadale², Cynthia Brown¹, Hemant Tiwari¹, Jasvinder Singh³ and Marcas Bamman¹, ¹University of Alabama at Birmingham, Birmingham, ²Central Arkansas Veterans Healthcare System, Little Rock, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Osteoarthritis (OA) had profound impacts on societal and patient-centered outcomes, including disability. As the first step to leverage the rich resource of the Million…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].